Serum Proteome Profiles in Stricturing Crohnʼs Disease

Townsend, P. T.; Qi-bin, Zhang; Shapiro, Jason; Webb-Robertson, Bobbie-Jo M.; Bramer, Lisa; Schepmoes, Athena; Weitz, Karl K.; Mallette, Meaghan; Moniz, Heather; Bright, Renee; Merrick, Marjorie; Shah, Samir A.; Sands, Bruce E.; LeLeiko, Neal S.

doi:10.1097/mib.0000000000000445

Cited by 28 publications

(24 citation statements)

References 43 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of techniques for proteomic analysis have been proposed, 90,91 with pilot studies indicating that proteomic profiling may be useful in the differentiation of IBD patients from healthy controls, 92,93 as well as in the differentiation of subtypes of IBD. 94 Early studies also suggest that protein profiling may also have a role in the prediction of response to biologic therapy among patients with IBD. 95 …”

Section: Future Directions For Biomarkersmentioning

confidence: 99%

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes

Burakoff²

2016

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Despite advances in our understanding of the pathophysiology underlying Inflammatory Bowel Disease (IBD), there remains a significant need for biomarkers that can differentiate between Crohn's Disease (CD) and Ulcerative Colitis (UC) with high sensitivity and specificity, in a cost-efficient manner. As the focus on personalized approaches to the delivery of medical treatment increases, new biomarkers are being developed to predict an individual's response to therapy as well as their overall disease course. In this review, we will outline many of the existing and recently developed biomarkers, detailing their role in the assessment of patients with IBD. We will identify opportunities for improvement in our biomarkers, including better differentiation between the subtypes of IBD. We will also discuss new targets and strategies in biomarker development, including combining modalities to create biomarker signatures to improve the ability to predict disease courses and response to therapy among individual patients.

show abstract

Section: Future Directions For Biomarkersmentioning

confidence: 99%

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes

Burakoff²

2016

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Discovering new biomarkers is a challenging process, and researchers have not been entirely successful at uncovering biomarkers that can reliably differentiate IBD patients from healthy controls, CD from UC, or predict disease outcome or response to treatment [8].…”

Section: Introductionmentioning

confidence: 99%

Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease

Manfredi

Conte

Barberis

et al. 2019

Journal of Proteomics

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of unknown etiology that can develop in any portion of the digestive tract but which has a high incidence especially in the terminal ileum and/or in the colon. The diagnosis and management of IBD, including Crohn's disease (CD) and ulcerative colitis (UC), is still challenging, and the presence of intestinal inflammation is, to date, a primary criterion for its diagnosis and differentiation from other diseases. Moreover, there is no decisive gold standard diagnostic test based on patient history and physical examination, supplemented with objective laboratory, radiological, endoscopic and histological findings.This study analyzed plasma proteins and fatty acids using mass spectrometry-based techniques. Quantitation of low-abundance plasma proteins was performed by depleting 14 high-abundance proteins, followed by tryptic digestion and LC-MS analysis, while fatty acids were analyzed using GC-MS.We used bioinformatic tools to identify several new potential biomarkers for an early and non-invasive diagnosis of IBD, and to differentiate CD from UC. Moreover, the diagnostic power of the MS-identified biomarkers was also corroborated by Western Blot and ELISA assays. Hence, we identified the biological functions and pathways involved in the various subsets of IBD.Coagulation, fibrinolysis and acute phase response processes were found to be strongly involved in the condition. The involvement of several fatty acids, such as anti-inflammatory mediators, was also identified. Finally, proteomic and lipidomic data were integrated by using combinatorial and multivariate analyses to discover new combined biomarkers and to study the molecular pathways involved in IBD.

show abstract

“…As prospective data collection from this novel cohort continues, OSCCAR represents a unique opportunity to study the natural history and course of IBD over time 25–28 . Other studies will continue to utilize the collected biospecimens to address translational questions 29 .…”

Section: Discussionmentioning

confidence: 99%

Incidence of Crohnʼs Disease and Ulcerative Colitis in Rhode Island

Shapiro

Zoëga

Shah

et al. 2016

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

Background Studies describing the incidence of Crohn’s disease (CD) and ulcerative colitis (UC) are uncommon in the United States (US). We sought to determine the incidence of CD and UC in the state of Rhode Island (RI). Methods The Ocean State Crohn’s and Colitis Area Registry (OSCCAR) is a state-based inception cohort of patients newly diagnosed with IBD in RI. To confirm a diagnosis of CD, UC or IBD unclassified (IBDU), the NIDDK IBD Genetics Consortium criteria were applied in a review of medical records from gastroenterology practices located in the state of RI and adjacent to the RI border in Massachusetts and Connecticut. Utilizing population-based data, we determined the statewide incidence of IBD in RI in 2008–2010. Results A total of 971 RI residents were diagnosed with IBD, including 444 with CD, 486 with UC and 41 with IBDU in 2008–2010. The overall age- and sex-adjusted IBD incidence was 30.2 (95% CI, 28.3–32.1) per 100,000 persons in this time frame with 13.9, 15.1 and 1.3 per 100,000 diagnosed with CD, UC and IBDU, respectively. Of the total incident cases in RI, 30% (n=291) were enrolled in OSCCAR for follow up. Conclusion The incidence of IBD in RI is higher than that previously reported by other population-based cohorts in the US. Prospective follow up of individuals enrolled in the community-based OSCCAR cohort is ongoing.

show abstract

Serum Proteome Profiles in Stricturing Crohnʼs Disease

Cited by 28 publications

References 43 publications

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease

Incidence of Crohnʼs Disease and Ulcerative Colitis in Rhode Island

Contact Info

Product

Resources

About